WO2001019864A1 - Polynucleotides codant pour des nouvelles proteines humaines du recepteur de l'angiotensine ii-1, leur procede de preparation et leur utilisation - Google Patents

Polynucleotides codant pour des nouvelles proteines humaines du recepteur de l'angiotensine ii-1, leur procede de preparation et leur utilisation Download PDF

Info

Publication number
WO2001019864A1
WO2001019864A1 PCT/CN2000/000268 CN0000268W WO0119864A1 WO 2001019864 A1 WO2001019864 A1 WO 2001019864A1 CN 0000268 W CN0000268 W CN 0000268W WO 0119864 A1 WO0119864 A1 WO 0119864A1
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
receptor
polypeptide
polynucleotide
related protein
Prior art date
Application number
PCT/CN2000/000268
Other languages
English (en)
Chinese (zh)
Inventor
Yumin Mao
Yi Xie
Original Assignee
Shanghai Biorigin Gene Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biorigin Gene Development Co. Ltd. filed Critical Shanghai Biorigin Gene Development Co. Ltd.
Priority to CN00812874.XA priority Critical patent/CN1373773A/zh
Publication of WO2001019864A1 publication Critical patent/WO2001019864A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention relates to a polynucleotide sequence encoding a novel human angiotensin II-1 receptor-related protein.
  • the present invention also relates to a method for preparing the polynucleotide sequence and a protein encoded by the same, and uses of the polynucleotide and a protein encoded by the same. Background of the invention
  • Angiotensin II receptors is a vasoactive peptide that interacts with special membrane-bound receptors in target tissues (eg, kidneys, adrenals, blood vessels).
  • target tissues eg, kidneys, adrenals, blood vessels.
  • angiotensin II receptors types AT1, AT2, and AT3, respectively
  • type 1, type 2, and type 3 three types of angiotensin II receptors (types AT1, AT2, and AT3, respectively) such as type 1, type 2, and type 3 have been obtained. They all have seven hydrophobic transmembrane domain structures in structure and can be simultaneously Combined with a pair of Gq proteins, its main biological function is signal transduction.
  • ATI and AT2 have 46% amino acid homology, of which ATI is composed of ATla and ATlb (both have the same coding region and different non-coding regions, the amino acid homology is higher than 90%), mainly in the heart of adults Vascular system, adrenal gland and intra-kidney expression are widely expressed in the entire body of the fetus and decline sharply with the birth of the fetus; AT2 is mainly expressed in the brain, adrenal medulla and ovary of adults.
  • ATI's intracellular signal transduction is mainly achieved by activating lipase C to produce two results, namely the activation of protein kinase C and the fixation of Ca 2+ .
  • ATRAP Angiotensin ⁇ -1 receptor-related protein
  • ATRAP mRNA is expressed in mouse kidney, heart, and testis, but not in mouse lung, liver, spleen, and brain.
  • the interaction of ATRAP and ATla receptors can be determined by affinity chromatography, fluorescence microscopy, and specific immunoprecipitation of two proteins.
  • Overexpression of ATRAP in COS-7 cells inhibits the activation of phospholipase C by the ATla receptor [Daviet L, et al., J Biol Chem 1999; 274: 17058-62].
  • ATI is an important component of the renin-angiotensin system (RA system), it can mediate physiological effects such as vasomotor contraction, water and salt metabolism, and vascular smooth muscle proliferation and function regulation. It is a key step of the RA system acting on effectors. It is also one of the pathogenic genes of hypertension genetics. Therefore, ATRAP can detect and treat a variety of cardiovascular diseases by interacting with ATI, such as detecting and treating coronary heart disease and primary disease. Hypertension and non-insulin-dependent diabetes mellitus are particularly preferably used for the treatment of coronary heart disease.
  • Another object of the present invention is to provide a polynucleotide sequence encoding an angiotensin type II-1 receptor-related protein.
  • Another object of the present invention is to provide a receptor comprising an angiotensin ⁇ -1 type receptor.
  • Recombinant expression vector of polynucleotide sequence of related protein Recombinant expression vector of polynucleotide sequence of related protein.
  • Another object of the present invention is to provide a method for producing angiotensin type II-1 receptor-related protein.
  • Another object of the present invention is to provide antibodies and antagonists against the angiotensin type II-1 receptor-related protein of the present invention.
  • Another object of the present invention is to provide a method for diagnosing and treating a disease associated with an abnormal function of angiotensin type II-1 receptor-related protein.
  • the present invention provides a substantially pure angiotensin type II-1 receptor-related protein consisting essentially of the amino acid sequence shown in SEQ ID NO: 2.
  • Angiotensin II-1 receptor-related proteins are characterized by a transmembrane domain.
  • the polynucleotide of the present invention is found from a cDNA library of human fetal brain tissue. It contains a full-length polynucleotide sequence of 1108 bases, and its open reading frame is SEQ ID NO: 1 at positions 56-535, encoding a human angiotensin II-1 receptor-related protein of 159 amino acids.
  • this polypeptide has 76% homology with ATRAP in rat testis tissue, and the polypeptide has conserved bases in the ATRAP gene family. It can be concluded that this new human ATRAP has the ATRAP gene family Similar structure and function.
  • isolated refers to the separation of a substance from its original environment (if it is a natural substance, the original environment is the natural environment).
  • polynucleotides and polypeptides in a natural state in a living cell are not isolated and purified, but the same polynucleotides or polypeptides are separated from other substances coexisting in the natural state. On, it is isolated and purified.
  • isolated angiotensin II-1 receptor-related protein or polypeptide means that angiotensin II-1 receptor-related protein is substantially free of other proteins, lipids, sugars, or Other substances.
  • Those skilled in the art can purify angiotensin II-1 receptor related protein using standard protein purification techniques. Substantially pure peptides can produce a single main band on a non-reduced polypropylene amidamine gel. The purity of angiotensin II-1 receptor related protein can be analyzed by amino acid sequence.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide, and is preferably a recombinant polypeptide.
  • the invention also includes fragments, derivatives and analogs of human angiotensin II-1 receptor related proteins.
  • fragment fragment
  • derivative derivative
  • analogs of human angiotensin II-1 receptor related proteins include fragments, derivatives and analogs of human angiotensin II-1 receptor related proteins.
  • a polypeptide fragment, derivative or analog of the present invention may be (i) a polypeptide having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues It may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a mature polypeptide with another compound (such as a compound that extends the half-life of a polypeptide, such as (Polyethylene glycol), a polypeptide formed by fusion, or (iv) a polypeptide formed by fusing an additional amino acid sequence to the polypeptide sequence (such as a leader sequence, a secretion sequence, or a sequence or protease sequence used to facilitate purification of the polypeptide).
  • the invention provides an isolated polynucleotide consisting essentially of a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2.
  • the polynucleotide sequence of the present invention includes the nucleotide sequence shown in SEQ ID NO: 1.
  • the polynucleotide of the present invention may be in the form of DNA or RNA.
  • DNA forms include cDNA, genomic DNA, or synthetic DNA.
  • DNA can be single-stranded or stranded.
  • DNA can be coding or non-coding.
  • the coding region sequence encoding the mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant thereof.
  • a “degenerate variant” in the present invention refers to a polynucleotide that encodes a protein or polypeptide having SEQ ID NO: 2 but is different from the polynucleotide sequence shown in SEQ ID NO: 1 due to the degeneracy of the genetic code. sequence.
  • the polynucleotide encoding the mature polypeptide of SEQ ID NO: 2 includes: a polynucleotide sequence encoding only the mature polypeptide; a polynucleotide encoding the mature polypeptide and various additional sequences; encoding a mature polypeptide (and optional additional coding sequences) And untranslated sequences.
  • polynucleotide encoding a polypeptide refers to a polynucleotide that includes a polynucleotide encoding the polypeptide and a polynucleotide that includes additional coding and / or non-coding sequences.
  • the invention also relates to variants of the polynucleotides described above, which encode polypeptides or fragments, analogs and derivatives of polypeptides having substantially the same amino acid sequence as the invention.
  • Variants of this polynucleotide can be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
  • an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .
  • the present invention also relates to a polynucleotide capable of hybridizing to a polynucleotide sequence described above under certain conditions, said sequence having at least 50%, preferably 70%, more preferably having 90% identity).
  • the present invention particularly relates to a polynucleotide capable of hybridizing to a polynucleotide according to the present invention under stringent conditions.
  • stringent conditions means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1% SDS, 60; or (2) addition of denaturation during hybridization Agent, such as 50% (v / v) formamide, 0.1% calf serum /0.1% Ficoll, 42 "C, etc .; or (3) hybridization occurs only when the identity between the two sequences is at least 95% or more, and more preferably 97% or more.
  • the hybridizable polynucleotide encodes The polypeptide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO: 2.
  • nucleic acid fragments capable of hybridizing to the sequences described above.
  • the "nucleic acid fragment” contains at least 15 nucleotides in length, preferably at least 20-30 nucleotides, more preferably at least 50-60 nucleotides, most preferably at least 100 nucleotides.
  • Nucleic acid fragments and above. Nucleic acid fragments can be used in nucleic acid amplification techniques (such as PCR) to identify and / or isolate polynucleotides encoding angiotensin II-1 receptor-related proteins.
  • the present invention also relates to a vector comprising a polynucleotide of the present invention, a host cell produced by a genetic engineering method using the vector of the present invention, and a method for producing a polypeptide according to the present invention by recombinant technology.
  • DNA sequence of the present invention can be obtained by various methods.
  • DNA is isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect homologous nucleotide sequences, and 2) antibody screening of expression libraries to detect cloned DNA fragments with common structural characteristics .
  • Generation of specific DNA fragment sequences encoding angiotensin II-1 receptor-related proteins can also be obtained by the following methods: 1) Isolating double-stranded DNA sequences from genomic DNA; 2) Chemically synthesizing DNA sequences to obtain double-stranded polypeptides DNA.
  • genomic DNA isolation is the most commonly used.
  • a method of direct chemical synthesis of the DNA sequence can also be used. If the entire sequence of the desired amino acid is unclear, direct chemical synthesis of the DNA sequence is not possible.
  • the alternative method is isolation of the cDNA sequence.
  • the standard method for isolating cDNA of interest is to isolate mRNA from donor cells that overexpress the gene and perform reverse transcription to form a plasmid or phage Somatic cDNA library. There are many mature techniques for extracting mRNA, and kits are also commercially available (Qiagene).
  • cDNA libraries are also a common method (Sambrook, et al, Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989).
  • Commercially available cDNA libraries are also available, such as different cDNA libraries from Clontech. When polymerase reaction technology is used in combination, even very small expression products can be cloned.
  • the genes of the present invention can be selected from these cDNA libraries by conventional methods. These methods include, but are not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) the presence or loss of function of a marker gene; (3) determination of the transcript of angiotensin II-1 receptor-related protein Level; (4) applying immunological techniques or measuring biological activity to detect the protein product of gene expression. The above methods can be used singly or in combination.
  • the probe used for hybridization should be homologous to any part of the polynucleotide of the present invention, and its length is at least 15 nucleotides, preferably 30 nucleotides, more preferably 50 Nucleotide, preferably more than 100 nucleotides. In addition, the length of the probe is usually within 2 kb, preferably within 1 kb.
  • the probe used here is generally a DNA sequence chemically synthesized based on the DNA sequence information of the gene of the present invention. The genes or fragments of the present invention can of course be used as probes. DNA probes can be labeled with radioactive isotopes, fluorescein, or thallium (such as alkaline phosphatase).
  • the protein product for detecting the expression of angiotensin II-1 receptor-related protein gene can be detected by immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA).
  • immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA).
  • a method of using a PCR technique to amplify DNA / RNA can be preferentially used to obtain the gene of the present invention.
  • the RACE method RACE: Rapid Amplification of cDNA Ends
  • the substance can be appropriately selected according to the sequence information of the present invention disclosed herein, and can be synthesized by a conventional method.
  • the amplified DNA / RNA fragments can be isolated and purified by conventional methods such as by gel electrophoresis.
  • nucleotide sequence of the gene of the present invention obtained as described above or various DNA fragments can be determined by a conventional method such as dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such nucleotide sequence determination can also be performed using commercial sequencing kits and the like. To obtain the full-length cDNA sequence, sequencing must be repeated. Sometimes it is necessary to determine the cDNA sequence of multiple clones in order to splice into a full-length cDNA sequence.
  • the polynucleotide sequence of the present invention can be used to express or produce recombinant angiotensin II-1 receptor-related protein (Science, 1984; 224: 1431). Generally there are the following steps:
  • a polynucleotide sequence encoding an angiotensin type II-1 receptor-related protein may be inserted into a recombinant expression vector.
  • the recombinant expression vectors used in the present invention include, but are not limited to, bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors.
  • Vectors suitable for use in the present invention include, but are not limited to: T7-based expression vectors (Rosenberg, et al., Gene, 1987, 56: 125) expressed in bacteria; pMSXND expression vectors (Lee and Lee) expressed in mammalian cells Nathans, Journal of Biochemistry 263: 3521, 1988) and baculovirus-derived vectors expressed in insect cells.
  • any plasmid and vector can be used as long as it can stably exist and replicate in the host.
  • An important feature of expression vectors is that they usually contain an origin of replication, Movers, marker genes and translation control elements.
  • an expression vector containing an angiotensin ⁇ -1 receptor-related protein-encoding DNA sequence and appropriate transcription / translation control signals can be used to construct an expression vector containing an angiotensin ⁇ -1 receptor-related protein-encoding DNA sequence and appropriate transcription / translation control signals. These methods include in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombination technology (Sambroook, et al. Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989).
  • the DNA sequence can be operably linked to an appropriate promoter in an expression vector to guide mRNA synthesis. Representative examples of these promoters are: the lac or trp promoter of E.
  • the expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.
  • the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
  • selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
  • GFP tetracycline
  • ampicillin resistance for E. coli.
  • Vectors containing the appropriate DNA sequences and appropriate promoters or control sequences described above can be used to transform appropriate host cells so that they can express proteins.
  • the host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell.
  • a prokaryotic cell such as a bacterial cell
  • a lower eukaryotic cell such as a yeast cell
  • a higher eukaryotic cell such as a mammalian cell.
  • Representative examples are: E. coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; plant cells; insect cells of Drosophila S2 or Sf; animals of CHO, COS or Bowes melanoma cells Cells etc.
  • Enhancer is DNA
  • the cis-acting factor usually about 10 to 300 base pairs, acts on a promoter to enhance gene transcription.
  • Illustrative examples include SV40 enhancers of 100 to 270 base pairs on the late side of the origin of replication, polyoma enhancers on the late side of the origin of replication, and adenovirus enhancers.
  • Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art.
  • the host is a prokaryote such as E. coli
  • competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated with the CaCl 2 method. The steps used are well known in the art. Alternatively, MgCl 2 is used. If necessary, transformation can also be performed by electroporation.
  • the host is a eukaryote, the following DNA transfection methods can be used: calcium phosphate co-precipitation method, conventional mechanical methods such as microinjection, electroporation, and liposome packaging.
  • the obtained transformants can be cultured by a conventional method and express the polypeptide encoded by the gene of the present invention.
  • the medium used in the culture may be selected from various conventional mediums. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
  • the recombinant polypeptide of interest may be coated in a cell or expressed on a cell membrane or secreted outside the cell.
  • recombinant proteins can be isolated and purified by various separation methods using their physical, chemical, and other properties. These methods are well known to those skilled in the art. More specifically, these methods include, but are not limited to: conventional renaturation, salting-out methods, centrifugation, osmotic shock breaking bacteria, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, Ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
  • Recombinant angiotensin II-1 receptor-related proteins or peptides have many uses It is particularly preferably used for the detection and treatment of various cardiovascular diseases, such as the detection and treatment of coronary heart disease, essential hypertension, and non-insulin-dependent diabetes mellitus. These uses include, but are not limited to: direct use as a drug to treat diseases caused by angiotensin II-1 receptor-associated protein hypofunction or loss, and for screening to promote or fight angiotensin II-1 receptor-associated protein Functional antibodies, polypeptides or other ligands. For example, antibodies can be used to activate or inhibit the function of angiotensin II-1 type receptor-related proteins. Screening the peptide library with the expressed angiotensin II-1 receptor-related protein can be used to find therapeutic polypeptide molecules that can inhibit or stimulate the function of angiotensin II-1 receptor-related protein.
  • the invention also provides methods for screening compounds, especially for identifying compounds that increase (agonist) or suppress (antagonist) angiotensin II-1 receptor related proteins.
  • These agonists or antagonists are particularly suitable for a variety of cardiac applications. Detection and treatment of vascular diseases, such as detection and treatment of coronary heart disease, essential hypertension and non-insulin-dependent diabetes.
  • Agonists enhance biological functions such as intracellular signaling of angiotensin II-1 receptor-related proteins, while antagonists prevent and treat disorders related to intracellular signaling, such as various cancers.
  • mammalian cells or angiotensin type II-1 receptor-associated proteins can be cultured in the presence of drugs with labeled angiotensin II-1 receptor-related proteins. The ability of the drug to increase or suppress this interaction is then determined.
  • Antagonists of angiotensin ⁇ -1 type receptor-related proteins include antibodies, compounds, receptor deletions, and the like that have been screened.
  • Antagonists of human angiotensin II-1 receptor-related proteins can bind to and eliminate human angiotensin II-1 receptor-related proteins, or inhibit human angiotensin II-1 receptor-related proteins Production, or binding to the active site of the polypeptide prevents the polypeptide from performing its biological function.
  • Antagonists of human angiotensin II-1 receptor-related proteins can be used to treat a variety of cardiovascular diseases, such as coronary heart disease, essential hypertension, and non-insulin-dependent diabetes mellitus.
  • angiotensin II-1 receptor-related protein When screening compounds as antagonists, angiotensin II-1 receptor-related protein can be added to the bioanalytical assay, and the interaction between angiotensin II-1 receptor-related protein and its receptor can be influenced by the determination of the compound To determine if the compound is an antagonist.
  • Receptor deletions and analogs that act as antagonists can be selected in the same way as the compounds selected above.
  • polypeptide of the present invention can be used for peptide mapping analysis.
  • the polypeptide can be specifically cleaved physically, chemically, or obscuredly, and subjected to one-dimensional or two-dimensional or three-dimensional gel electrophoresis analysis.
  • antibodies against angiotensin II-1 receptor-related protein epitopes include, but are not limited to, polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments, and fragments produced by Fab expression libraries.
  • Antibodies against angiotensin II-1 receptor-related proteins can be used in immunohistochemical techniques to detect angiotensin II-1 receptor-related proteins in biopsy specimens.
  • Monoclonal antibodies that bind to angiotensin II-1 receptor-related proteins can also be labeled with radioisotopes and injected into the body to track their location and distribution.
  • This radiolabeled antibody can be used as a non-invasive diagnostic method to locate tumor cells and determine whether they metastasize.
  • the antibodies of the present invention can be used to treat or diagnose diseases related to angiotensin II-1 receptor-related proteins, and are particularly preferred for a variety of cardiovascular diseases, such as coronary heart disease, essential hypertension, and non-insulin-dependent diabetes mellitus. .
  • Administration of an appropriate dose of antibody can stimulate or block the production or activity of angiotensin type II-1 receptor related proteins.
  • Antibodies can also be used to design immunotoxins that target a particular part of the body.
  • monoclonal antibodies with high affinity for angiotensin II-1 receptor-related proteins can covalently bind to bacterial or plant toxins (such as diphtheria toxin, ricin, ormosine, etc.). Together.
  • a common method is to attack the amino group of an antibody with a sulfhydryl crosslinker such as SPDP and bind the toxin to the antibody through the exchange of disulfide bonds.
  • This hybrid antibody can be used to kill angiotensin II-1 receptors Related protein positive cells.
  • Polyclonal antibodies can be produced by immunizing animals such as rabbits, mice, and rats with angiotensin II-1 receptor-related proteins or peptides.
  • adjuvants can be used to enhance the immune response, including but not limited to Freund's adjuvant.
  • Monoclonal antibodies to angiotensin II-1 receptor-related proteins can be produced by hybridoma technology (Kohler and Milstein. Ature, 1975, 256: 495-497). Chimeric antibodies that bind human constant regions to non-human-derived variable regions can be produced using existing techniques (Morrison et al., PNAS, 1985, 81: 6851). The existing technology for producing single-chain antibodies (U.S. Pat No. 4946778) can also be used to produce single-chain antibodies against angiotensin II receptor-related proteins.
  • Polypeptide molecules capable of binding to angiotensin II-1 receptor-related proteins can be obtained by screening a random peptide library composed of various possible combinations of amino acids bound to a solid phase. During screening, angiotensin II-1 receptor-related protein molecules must be labeled.
  • the polypeptide of the present invention can be used in combination with a suitable pharmaceutical carrier.
  • This composition comprises a therapeutically effective amount of a polypeptide, and a pharmaceutically acceptable carrier or excipient.
  • suitable pharmaceutical carrier include, but are not limited to, saline, buffered saline, glucose, water, glycol, ethanol, and combinations thereof. The person skilled in the art knows how to adapt these formulations to the mode of administration.
  • the present invention also provides a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the present invention.
  • these containers there may be instructional instructions given by government agencies that manufacture, use, or sell pharmaceuticals or biological products, which reminders permit their administration on the human body by government agencies that manufacture, use, or sell them.
  • the polypeptides of the invention can be used in combination with other therapeutic compounds.
  • the pharmaceutical composition can be administered in a convenient manner, such as by topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes.
  • Angiotensin II-1 receptor-related protein is administered in an amount effective to treat and / or prevent a particular indication.
  • the amount and dose range of angiotensin II-1 receptor-related protein to be administered to a patient will depend on many factors, such as the mode of administration, the natural conditions of the subject, and the judgment of the diagnostician.
  • the invention also relates to a diagnostic test method for quantitatively and locally detecting the level of angiotensin II-1 receptor-associated protein.
  • diagnostic tests are well known in the art and include FISH assays and radioimmunoassays.
  • Angiotensin II-1 receptor-associated protein levels detected in the test can be used to explain the importance of angiotensin II-1 receptor-associated proteins in various diseases and to diagnose diseases in which ATRAP can play a role.
  • Polynucleotides encoding angiotensin ⁇ -1 type receptor-related protein can also be used for the diagnosis and treatment of angiotensin ⁇ -1 type receptor-related protein-related diseases, and is particularly preferred for a variety of cardiovascular diseases such as detection and treatment Coronary heart disease, essential hypertension and non-insulin-dependent diabetes mellitus.
  • angiotensin II-1 receptor-related protein polynucleotides can be used to detect expression of angiotensin II-1 receptor-related protein or angiotensin II-1 receptor-related protein in disease states Abnormal expression.
  • the DNA sequence of angiotensin II-1 receptor-related protein can be used to hybridize biopsy specimens to determine the abnormal expression of angiotensin II-1 receptor-related protein.
  • Hybridization techniques include Southern blotting, Northern blotting, in situ hybridization, and the like. These techniques and methods are publicly available and mature, and related kits are commercially available.
  • a part or all of the polynucleotide of the present invention can be used as a probe to be fixed on a microarray or a DNA chip for analyzing differential expression analysis and gene diagnosis of genes in a tissue.
  • Angiotensin II-1 receptor-related protein-specific primers can be used for RNA-polymerase chain reaction (RT-PCR) in vitro amplification to detect the transcription products of angiotensin II-1 receptor-related protein.
  • Detecting mutations in the angiotensin II-1 receptor-related protein gene can also be used to diagnose angiotensin II-1 receptor-related protein-related diseases, and is particularly preferred for a variety of cardiovascular diseases such as detecting and treating coronary heart disease, Essential hypertension and non-insulin-dependent diabetes mellitus.
  • Angiotensin II-1 receptor-associated protein mutations include point mutations, translocations, deletions, recombination, and any other abnormalities compared to the DNA sequence of normal wild-type angiotensin II-1 receptor-related proteins. Mutations can be detected using existing techniques such as Southern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, mutations may affect protein expression, so Northern blots and Western blots can be used to indirectly determine whether a gene is mutated.
  • the sequences of the invention are also valuable for chromosome identification.
  • This sequence specifically targets the specific position of a single human chromosome and can hybridize to this chromosome.
  • few chromosome labeling reagents based on actual sequence data can be used to label the chromosomal position of the beam.
  • the action of D N A on chromosomes is an important first step in correlating these sequences with disease-related solids.
  • PCR primers preferably 15-25 bp
  • the computer analysis of c D N A quickly selected primers that did not cross an exon of the genome D N A, thereby complicating the amplification procedure. These primers were then used for PCR to screen somatic hybrid cells containing a single human chromosome. Only these hybrid cells containing human genes corresponding to the primers will produce amplified fragments.
  • PCR localization of somatic hybrid cells is a quick way to localize DNA to specific chromosomes.
  • oligonucleotide primers of the present invention by a similar method, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization.
  • Other similar strategies that can be used for chromosome localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and pre-selection of hybrids to construct Construct a chromosome-specific cDNA library.
  • Fluorescent in situ hybridization of cDNA clones with metaphase chromosomes allows precise chromosomal localization in one step.
  • FISH Fluorescent in situ hybridization
  • the physical location of the sequence on the chromosome can be correlated with the gene map data.
  • These data can be found in, for example, V. Mckusick, Mendelian Inheritance in Man I (available online with Johns Hopkins University Welch Medical Library). Linkage analysis can then be used to determine the relationship of genes to diseases that have been mapped to some chromosomal regions.
  • c D N A or genomic sequence between the affected and unaffected individuals needs to be determined. If mutations are observed in some or all diseased individuals, but not in any normal individuals, mutations may be the cause of the disease.
  • the precise location of c DNA in chromosomal regions associated with disease can be one of 50 to 500 potentially pathogenic genes (assuming 1 megabase mapping Resolution and every 20kb—genes).
  • Comparing diseased and unaffected individuals usually involves first looking for structural changes in the chromosome, such as deletions or translocations that are visible from chromosomal extension or detectable with a PCR based on the c D N A sequence. Finally, the complete sequencing of the genes of several individuals is needed to confirm the existence of mutations and the differences between mutations and polymorphisms.
  • Angiotensin II-1 receptor-related protein polynucleotides can also be used for a variety of therapeutic purposes, and are particularly preferred for a variety of cardiovascular diseases, such as detection and treatment of coronary heart disease, essential hypertension, and non-insulin-dependent diabetes.
  • Gene therapy technology can be used to treat cell proliferation caused by angiotensin II-1 receptor-related protein expression or abnormal / inactive angiotensin II-1 receptor-related protein expression Colonization, development or metabolic abnormalities.
  • Recombinant gene therapy vectors (such as viral vectors) can be designed to express variant angiotensin II-1 receptor-related proteins and to inhibit endogenous angiotensin II-1 receptor-related protein activity.
  • a variant angiotensin II-1 receptor-associated protein may be a truncated angiotensin II-1 receptor-associated protein that lacks a signaling domain, although it can bind to downstream substrates But lacks signaling activity. Therefore, the recombinant gene therapy vector can be used to treat diseases caused by abnormal expression or activity of angiotensin II-1 receptor-related protein.
  • Virus-derived expression vectors such as retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, and parvovirus can be used to transfer angiotensin II-type 1 receptor-related protein genes into cells. Constructed to carry angiotensin
  • recombinant viral vectors of type II-1 receptor-associated protein genes can be found in existing literature (Sambrook, et al.).
  • the recombinant angiotensin II-1 receptor-related protein gene can be packaged into liposomes and transferred into cells.
  • Oligonucleotides including antisense R A and DNA
  • ribozymes that inhibit angiotensin II-1 receptor-related protein mRNA are also within the scope of the present invention.
  • a ribozyme is an enzyme-like RNA molecule that specifically cleaves specific RNA. Its mechanism of action is that the ribozyme molecule specifically hybridizes with a complementary target RNA for endonucleation.
  • Antisense RNA, DNA, and ribozymes can be obtained by any existing technology for synthesizing RNA or DNA. For example, solid-phase phosphate amide chemical synthesis technology has been widely used for oligonucleotides.
  • Antisense RNA molecules can be obtained by in vitro or in vivo transcription of a DNA sequence encoding the RNA. This DNA sequence has been integrated downstream of the vector's RNA polymerase promoter. In order to increase the stability of the nucleic acid molecule, it can be modified in a variety of ways, such as increasing the sequence length on both sides, and the linkage between ribonucleosides using phosphothioester or peptide bonds instead of phosphodiester bonds.
  • Methods for introducing a polynucleotide into a tissue or cell include: injecting the polynucleotide directly into a tissue in vivo; or introducing the polynucleotide into a cell in vitro through a vector (such as a virus, phage, or plasmid), and then introducing the cell Transplanted into the body, etc.
  • a vector such as a virus, phage, or plasmid
  • the polypeptides and polynucleotides of the present invention also have other uses.
  • the polypeptides of the present invention can be used for identification of peptide fingerprints, and the coding sequences or fragments thereof of the present invention can be used to make gene chips or microarrays.
  • Example 1 Cloning of a polynucleotide encoding a human angiotensin II-1 receptor-related protein
  • Total human fetal brain RNA was extracted by one-step method with guanidine isothiocyanate / phenol / chloroform.
  • Poly (A) mRNA was isolated from total RNA using Quik mRNA Isolation Kit (Qiagene). 2 g poly (A) mRNA was reverse transcribed to form cDNA. Smart cDNA Cloning Kit (purchased from Clontech) was used to orient the cDNA fragment into At the multiple cloning site of the vector, E. coli DH5a was transformed to form a cDNA library. A total of 3028 clones were obtained. The dideoxy method was used to determine the sequence of the 5 and 3 'ends of all clones.
  • the determined cDNA sequence was compared with the existing public DNA sequence database, and it was found that the DNA sequence of one clone (0894e01) was new DNA.
  • the DNA sequence contained in the 0894e01 clone was determined in both directions by synthesizing a series of primers.
  • Computer analysis shows that the full-length cDNA contained in the 0894e01 clone is a new DNA sequence (as shown in Seq ID Nol), and has a 479bp ORF from 56th to 535th positions, encoding a new protein (such as Seq ID No 2), the sequence is named pBS-0894e01. This protein is named human angiotensin II-1 receptor-related protein.
  • Example 2 Cloning of human angiotensin ⁇ -1 receptor-related egg by RT-PCR White:
  • CDNA was synthesized using fetal brain cell total RNA as a template and oligo-dT as a primer for reverse transcription reaction. After purification with Qiagen's kit, PCR amplification was performed with the following primers: Forward primer Fl 5, -GGGAGCCTAGGAGCCCCC-3, located at Start of SEQ ID NO1; reverse primer R1: 5'- GAATTCCCCAAACTTTAATG-3 'is located at 1088-1108bp of SEQ ID NO1.
  • Amplification reaction conditions 50 mmol / L KCl, 10 mmol / L Tris-Cl, (pH 8.5), 1.5 mmol / L MgCl 2 , 20 ( ⁇ mol / L dNTP, 25 pmol primers, 2.5 in a reaction volume of 50 ⁇ 1) Taq DNA polymerase of U.
  • Set ⁇ -actin at the same time during RT-PCR The positive control and template blank were negative controls.
  • the polynucleotide sequence of the human angiotensin II-1 receptor-related protein provided by the present invention and its encoded protein sequence are compared with databases of Genbank ⁇ Swissport and other databases for homology.
  • the program used for searching is Blast (Basic local Alignment search tool) (1993, Proceedings of the National Academy of Sciences, 90: 5873-5877), Blast can find many homologous genes, among which the gene with the highest homology with the gene of the present invention, the protein encoded by it is in the Genbank standard. Accession number is AF102548. These retrieved gene or protein sequences can be retrieved from the Genbank database.
  • the recalled sequences can be compared using the Pileup (multi-sequence) and Gap (two-sequence) programs in the GCG software package. Protein function predictions can be analyzed using the Motif program.
  • the results of the homology search show that the human angiotensin II-1 receptor-related protein provided by the present invention is related to the rat angiotensin II-1 receptor The protein has 76% homology, and the comparison of isogenicity is as follows.
  • This method involves acid guanidinium thiocyanate phenol-chloroform extraction. That is, 4M guanidinium isothiocyanate-25mM sodium citrate, 0.2M sodium acetate (pH4.0) were used to homogenize the tissue, and 1 volume of benzylphenol and 1/5 volume of chloroform-isoamyl alcohol (49: 1) were added. ), Mix and centrifuge. Aspirate the aqueous layer, add isopropanol (0.8 vol) and mix Centrifuge to obtain RNA pellet.
  • RNA pellet was washed with 70% ethanol, dried and dissolved in water. Electrophoresis was performed on a 1.2% agarose gel containing 2 g of RNA on 20 mM 3- (N-morpholino) propanesulfonic acid (pH 7.0)-5 mM sodium acetate-ImM EDTA-2.2M formaldehyde. Then transferred to nitrocellulose. the probe (about 2xl0 6 cpm / ml) 32 P- labeled at 42 in a solution "hybridization overnight, the solution containing 50% formamide -25mM KH 2 P0 4 (pH7.
  • Example 5 In vitro expression, isolation and purification of recombinant human angiotensin II-1 receptor-related protein
  • a pair of primers were designed at the start codon and the stop codon of the angiotensin type II-1 receptor-related protein gene, respectively, with 5 and ends carrying BamHI and EcoRI restriction sites.
  • the plasmid pBS-0894e01 was used as a template for PCR amplification to obtain the coding region of angiotensin II-1 receptor-related protein gene.
  • the amplified fragment was inserted into the expression vector PGEX-2T (purchased from Pharmacia Biotech) and transformed into E. coli DH5a.
  • PGEX-2T purchased from Pharmacia Biotech
  • E. coli DH5a E. coli DH5a
  • E. coli DH5a E. coli DH5a
  • five white recombinant transformants were screened for DNA sequence analysis. The result is exactly the same as the gene coding region sequence in pBS-0894e01.
  • the recombinant clone can express the GST-ATRAP fusion protein, and the clo
  • Polypeptide synthesizer (PE-ABI) was used to synthesize the following angiotensin II-1 receptor-related protein-specific polypeptide: Ala-Pro-Ala-Asp-Pro-Phe-Ala-Val-Pro-Glu (p. 141) -150 digits).
  • the polypeptide is coupled to hemocyanin and bovine serum albumin to form a complex, respectively.
  • Rabbits were immunized with 4 mg of the hemocyanin polypeptide complex plus complete Freund's adjuvant, and 15 days later, the hemocyanin polypeptide complex plus incomplete Freund's adjuvant was used to boost immunity once.
  • a titer plate coated with a 15 g / ml bovine serum albumin peptide complex was used as an ELISA to determine antibody titers in rabbit serum.
  • Protein A-Sepharose was used to isolate total IgG from antibody-positive rabbit serum.
  • the peptide was bound to a cyanogen bromide-activated Sepharose 4B column, and anti-peptide antibodies were separated from the total IgG by affinity chromatography.
  • the immunoprecipitation method demonstrated that the purified antibody can specifically bind to the angiotensin type II-1 receptor-related protein of the present invention.
  • Example 7 Yeast two-hybrid experiment
  • Mouse ATla receptor (: terminal cytoplasmic domain (ATla C-ter; amino acid 297-359)
  • the Gal4 binding domain fused to the yeast shuttle vector pBD-Gal4 (Stratagene) is amplified by PCR.
  • ATla receptor tails (ATla C-ter 349, 339, and 329) were subcloned into pBD-Gal4 by PCR amplification using antisense primers containing specific site stop codons.
  • angiotensin type II-1 receptor-related protein was inserted into the plasmid pAD-Gal4 (Stratagene). Two-hybrid screening:
  • Yeast strain YRG-2 (Stratagene) containing two Gal4-induced reporter genes (HIS3 and LacZ) and ATla C-ter angiotensin ⁇ -1 type receptor-related protein hybrid expression plasmid were co-transcribed.
  • Defective (Try-Leu'His) medium was cultured for three days, His + colonies were added to the selective medium, and nitrocellulose membrane culture was performed to measure the P-galactosidase activity. The results are shown in Table 1, Table 1 and ATRAP and ATla receptors. Tail deletion mutant interactions
  • Gal4 binding domain hybrids Gal4 active domain hybrids Gal unit ° /. Combined%

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un nouveau type de protéines humaines du récepteur de l'angiotensine II-1 et des polyucléotides codant les polypeptides, ainsi qu'un procédé de production des polypeptides par des procédés de recombinaison. L'invention porte également sur le procédé d'utilisation des polypeptides et des polynucléotides pour la prévention ou le traitement de divers types de maladies, telles que les maladies cardiovasculaires, les maladies coronariennes, l'hypertension artérielle essentielle et le diabète non-insulinodépendant. L'anticorps et l'antagoniste du polypeptide ainsi que leur utilisation thérapeutique sont également décrits. Par ailleurs, l'invention porte sur l'utilisation de polynucléotides codant pour les nouvelles protéines humaines du récepteur de l'angiotensine II-1.
PCT/CN2000/000268 1999-09-10 2000-09-11 Polynucleotides codant pour des nouvelles proteines humaines du recepteur de l'angiotensine ii-1, leur procede de preparation et leur utilisation WO2001019864A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN00812874.XA CN1373773A (zh) 1999-09-10 2000-09-11 一种编码新的人血管紧张素ii－1受体相关蛋白的多核苷酸及其制备方法和应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN99116857.7 1999-09-10
CN99116857A CN1288057A (zh) 1999-09-10 1999-09-10 一种编码新的人血管紧张素ⅱ－1受体相关蛋白的基因及其应用和制备方法

Publications (1)

Publication Number Publication Date
WO2001019864A1 true WO2001019864A1 (fr) 2001-03-22

Family

ID=5279527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2000/000268 WO2001019864A1 (fr) 1999-09-10 2000-09-11 Polynucleotides codant pour des nouvelles proteines humaines du recepteur de l'angiotensine ii-1, leur procede de preparation et leur utilisation

Country Status (2)

Country Link
CN (1) CN1288057A (fr)
WO (1) WO2001019864A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8176959B2 (en) * 2009-01-12 2012-05-15 Lamus Enterprises Inc. Multi-functional tape applicator
CN108948183B (zh) * 2018-06-05 2022-01-28 武汉华纪元生物技术开发有限公司 α1受体和AT1受体抗原类似物多肽及其抗体检测试剂盒和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENOMICS, vol. 41, no. 3, 1997, pages 301 - 308 *
J. BIOL. CHEM., vol. 274, no. 24, 11 June 1999 (1999-06-11), pages 17058 - 17062 *

Also Published As

Publication number Publication date
CN1288057A (zh) 2001-03-21

Similar Documents

Publication Publication Date Title
WO2001019999A1 (fr) Gene codant une nouvelle threonyl-arnt synthase, ses utilisations et procedes de preparation
WO2002051867A1 (fr) Nouveau facteur 8.8 polypeptidique liberant de la corticotrophine et polynucleotide codant ledit polypeptide
WO2001019864A1 (fr) Polynucleotides codant pour des nouvelles proteines humaines du recepteur de l'angiotensine ii-1, leur procede de preparation et leur utilisation
JP2001513640A (ja) 新規なヒト膜貫通４スーパーファミリータンパク質
WO2001038522A1 (fr) Nouveau polypeptide, histone humaine h2a.21, et polynucleotide codant pour ce polypeptide
US6919430B1 (en) Polypeptide—human galectin 15 and a polynucleotide encoding the same
WO2001031030A1 (fr) Nouveau polypeptide, phosphodiesterase 21 humaine de type acide sphingomyelinase, et polynucleotide codant pour ce polypeptide
WO2001029228A1 (fr) Nouveau polypeptide, caseine kinase humaine 48, et polynucleotide codant pour ce polypeptide
JPH1132785A (ja) 慢性腎不全の標的およびマーカーであるｃｒｆｇ−１
WO2001038379A1 (fr) Nouvelle proteine ribosomique humaine l23 a base d'un polypeptide et polynucleotide codant cette proteine
WO2001047983A1 (fr) Nouveau polypeptide, facteur de liberation de la corticotrophine 13, et polynucleotide codant pour ce polypeptide
WO2001030818A1 (fr) Nouveau polypeptide, proteine de liaison 33 a l'arn, et polynucleotide codant pour ce polypeptide
WO2001038389A1 (fr) Nouvelle proteine ribosomique l14.22 a base d'un polypeptide et polynucleotide codant cette proteine
WO2001030840A1 (fr) Nouveau polypeptide, une proteine 57 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001032863A1 (fr) Nouveau polypeptide, proteine humaine 12 associee a l'apoptose (sag), et polynucleotide codant pour ce polypeptide
WO2001029076A1 (fr) Nouveau polypeptide, une proteine-22 humaine p24, et polynucleotide codant pour ce polypeptide
WO2001038370A1 (fr) Nouvelle sous-unite 49 de l'activateur de transcription polypeptidique et polynucleotide codant ce polypeptide
WO2001027148A1 (fr) Nouveau polypeptide, facteur homo 56 riche en glutamine(q), et polynucleotide codant pour ce polypeptide
WO2001023423A1 (fr) Nouveau gene comprenant le domaine ww et codant le polypeptide humain interagissant avec l'huntingtine, methode de production dudit gene et application correspondante
WO2001040297A1 (fr) Nouveau polypeptide, proteine nucleaire de transition humaine 10 contenant un domaine de liaison atp/gtp, et polynucleotide codant pour ce polypeptide
WO2001029080A1 (fr) Nouveau polypeptide, une proteine humaine hmg-13, et polynucleotide codant pour ce polypeptide
WO2001046441A1 (fr) Nouveau polypeptide, proteine humaine shc 43, et polynucleotide codant pour ce polypeptide
WO2001064727A1 (fr) Nouveau polypeptide, adenosinate cyclase soluble 25 de souris, et polynucleotide codant pour ce polypeptide
WO2001030819A1 (fr) Nouveau polypeptide, tropomoduline humaine 39, et polynucleotide codant pour ce polypeptide
WO2001029229A1 (fr) Nouveau polypeptide, proteine humaine 20 de liaison de retinoblastome et polynucleotide le codant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CN JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 00812874X

Country of ref document: CN

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP